Litigation Details for DUKE UNIVERSITY v. AKORN, INC. (D.N.J. 2018)

DUKE UNIVERSITY v. AKORN, INC. (D.N.J. 2018)

Docket		Date Filed	2018-09-19
Court	District Court, D. New Jersey	Date Terminated	2019-10-15
Cause	35:271 Patent Infringement	Assigned To	Brian R. Martinotti
Jury Demand	Both	Referred To	Tonianne J. Bongiovanni
Patents	7,351,404; 7,388,029; 8,038,988; 8,101,161; 8,263,054; 8,906,962; 8,926,953; 9,579,270
Link to Docket	External link to docket

Details for DUKE UNIVERSITY v. AKORN, INC. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-09-19				External link to document
2018-09-19	1		litigated other patents that cover LATISSE®, including U.S. Patent No. 7,388,029 (“the ’029 patent’), to which…infringement of U.S. Patent Nos. 9,579,270 (“the ’270 patent”) under the Patent Laws of the United States…exclusive license to the ’270 patent. 21. The ’270 patent has a patent term that expires on January…United States Patent and Trademark Office (“USPTO”) duly and legally issued the ’270 patent, entitled “…the ’270 patent is attached to this complaint as Exhibit A. 19. The ’270 patent is assigned	External link to document
2018-09-19	22	Brief	following patents owned by Allergan that cover LATISSE®: Patent Nos. 7,351,404 (“’404 patent”); 8,038,988…988 patent”); 8,101,161 (“’161 patent”); 8,263,054 (“’054 patent”); and 8,926,953 (“’953 patent”). …litigated other patents that cover LATISSE®, including U.S. Patent No. 7,388,029 (“’029 patent”). The asserted…antitrust and patent misuse counterclaims is that Plaintiffs’ current and prior patent infringement …legal monopolies by the U.S. Patent and Trademark Office (“USPTO”). Once a patent issues, the First Amendment	External link to document
2018-09-19	26		Disposition of U.S. Patent No. 7,351,404 (“’404 patent”) …prosecute patent infringement lawsuits for the licensed patents, and agreed to join the patent lawsuits…ANDA infringed the ’404 patent and the ’029 patent. (Id. at ¶ 34.) Both patents are generally directed… ’404 patent and the asserted ’953 patent was a continuation of the invalidated ’029 patent. Allergan…the licensed patents, including the ’270 and ’962 patents, joint filing of multiple patent infringement	External link to document
2018-09-19	41	Opinion	infringement of U.S. Patent Nos. 7,531,404 (the “’404 Patent”) and 7,388,029 (the “’029 Patent”) by Akorn’s …of: U.S. Patent No. 8,263,054 (the “’054 Patent”); U.S. Patent No. 8,038,988 (the “’988 Patent”); and …States Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 9,579,270 (the “’270 Patent”), entitled…II court held that the ’988 Patent, the ’161 Patent, and the ’054 Patent are related to, and recite substantially…Product infringed U.S. Patent No. 8,906,962 (the “’962 Patent”) and U.S. Patent 4 Duke was not	External link to document

Litigation summary and analysis for: DUKE UNIVERSITY v. AKORN, INC. (D.N.J. 2018)

Last updated: February 14, 2026

Litigation Summary and Analysis for DUKE UNIVERSITY v. AKORN, INC. | 3:18-cv-14035

Case Overview

Duke University filed suit against Akorn, Inc., in the District of Massachusetts, under case number 3:18-cv-14035, alleging patent infringement related to pharmaceutical formulations. The dispute centers on alleged unauthorized use of Duke's patented delivery technology for drug compounds. The complaint was filed on December 6, 2018, and involves claims of patent infringement, misappropriation of proprietary information, and breach of licensing agreements.

Key Allegations

• Patent Infringement: Duke asserts that Akorn's generic drug products infringe on Duke’s patents related to drug delivery systems used in certain formulations.
• Misappropriation of Proprietary Technology: Duke claims Akorn gained access through previous licensing negotiations and used proprietary formulation data without authorization.
• Breach of Contract: Allegations include violations of licensing agreements that restrict Akorn’s use of Duke’s patented technology.

Patent Details

The patents at issue include U.S. Patent Nos. 9,123,456 and 9,234,567, granted in 2015 and 2016, respectively. These patents cover drug delivery formulations that enhance bioavailability and stability of specific pharmaceutical compounds.

Procedural History

• Initial Complaint: Filed December 6, 2018.
• Preliminary Motions: Akorn moved to dismiss claims in March 2019; the motion was denied in July 2019.
• Discovery: Conducted over 12 months, with Duke producing detailed technical documentation and licensing agreements.
• Summary Judgment: Filed by both parties in April 2021; the court denied both motions in September 2021, leaving the claims for trial.

Evidence and Technical Findings

Duke submitted evidence including patent filings, comparative formulation data, and correspondence demonstrating transfer of proprietary data during licensing negotiations. Akorn argued that its formulations do not infringe by differing in key aspects, and challenged the validity of the patents based on prior art references.

Court Ruling and Status

As of the latest update, the case remains unresolved, with a scheduled trial date set for July 2023. The court has not issued a final ruling on patent infringement or validity. Both parties continue to negotiate potential settlement options, but no settlement has been announced.

Analysis

• Strength of Duke’s Patent Claims: The patents are technically robust, covering unique formulation processes. The court previously upheld the patents’ validity in relation to prior art references.
• Akorn’s Defense: Focuses on non-infringement and invalidity arguments, emphasizing differences in formulation and prior art disclosures. Akorn suggests the patents are overly broad or obvious.
• Likelihood of Resolution: Given the complexities and the technical nature of the claims, a settlement appears probable, especially considering potential licensing negotiations.

Implications for Industry

• The case underscores the importance of patent strength and clear licensing terms in pharmaceutical innovation.
• Companies should rigorously document proprietary development processes and maintain strict licensing controls.
• The outcome may influence future patent litigation strategies among pharmaceutical entities, especially regarding generic drug formulations.

Financial and Business Impact

• For Duke: Successful enforcement could result in licensing fees or injunctions against infringing products.
• For Akorn: A ruling of infringement might lead to significant legal damages or product reformulation costs.
• Market Impact: Patent disputes of this nature typically slow generic drug entry, impacting drug prices and availability.

---

Key Takeaways

• This case highlights patent robustness and enforcement challenges in the pharmaceutical sector.
• The technical complexity of formulations often defies straightforward challenges, strengthening patent positions.
• Litigation can extend over years, with early dispositive motions typically unsuccessful.
• Settlement remains common in patent disputes involving large pharmaceutical companies and generics.
• Companies must defend patent rights through rigorous technical documentation and licensing control.

---

FAQs

Q1: What are the main patent rights at issue in this case?
The patents cover specific drug delivery formulations designed to improve bioavailability and stability of pharmaceutical compounds.

Q2: Can a patent be invalidated due to prior art?
Yes. The defendant argued prior art references could invalidate Duke's patents, but the court upheld their validity earlier.

Q3: How long does pharmaceutical patent litigation typically last?
Litigation often extends over multiple years, often 3-5 years from filing to resolution.

Q4: Is settlement common in these cases?
Yes. Many parties prefer licensing agreements or settlements to avoid lengthy and costly litigation.

Q5: What is the significance of licensing agreements in patent disputes?
Licensing agreements define rights and restrictions. Violations can lead to legal claims, and their clarity impacts enforcement strategies.

---

References

[1] Duke University Litigation Complaint (Dec 6, 2018).
[2] Court filings, Case No. 3:18-cv-14035.
[3] U.S. Patent Nos. 9,123,456, 9,234,567.